Acquiring Company
Esperion Therapeutics
Acquired Company
Corstasis Therapeutics
Ann ArborHendersonBiotechnologyHealth CareTherapeuticsPharmaceuticalpharmaceuticalsBiotechnologyHealth CareDescription
On March 2, 2026, Esperion Therapeutics, Inc. entered into an Agreement and Plan of Merger with Corstasis Therapeutics Inc. and its wholly-owned subsidiary. This merger will result in Corstasis becoming a wholly-owned subsidiary of Esperion. The aggregate cash consideration for the transaction is set at $75 million, subject to customary adjustments.
Who to call at Esperion Therapeutics, and when
When Esperion Therapeutics changes hands, the new owners review vendors, systems and leadership. That is when the door opens.
- An alert the day Esperion Therapeutics raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Esperion Therapeutics, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Esperion Therapeutics. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Esperion Therapeutics makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Frequently asked
Who acquired Corstasis Therapeutics?
Corstasis Therapeutics was acquired by Esperion Therapeutics, based in Ann Arbor. The deal was reported on March 3, 2026. Esperion Therapeutics is a pharmaceutical company based in Ann Arbor, Michigan, focused on developing and commercializing innovative medicines for patients at risk for cardiovascular and cardiometabolic diseases. Esperion Therapeutics is privately held and operates in Biotechnology.
When did Esperion Therapeutics acquire Corstasis Therapeutics?
Esperion Therapeutics's acquisition of Corstasis Therapeutics was reported on March 3, 2026. On March 2, 2026, Esperion Therapeutics, Inc. entered into an Agreement and Plan of Merger with Corstasis Therapeutics Inc. and its wholly-owned subsidiary. This merger will result in Corstasis becoming a wholly-owned subsidiary of Esperion. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does Corstasis Therapeutics do?
Corstasis Therapeutics Inc. is a clinical-stage biotechnology company pioneering outpatient therapies for fluid overload associated with congestive heart failure, liver disease, and chronic kidney disease. It is privately held, operating in Biotechnology, and is based in Henderson.
This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.